文献速递神经创伤脑血管病外科

辅助脑膜中动脉栓塞治疗非急性硬膜下血肿:GRADE评级荟萃分析与试验序贯分析

Adjunctive middle meningeal artery embolization for non-acute subdural hematoma: A GRADE-assessed meta-analysis and trial sequential analysis on randomized trials.
PubMed 文献 · Acta Neurochir (Wien) · 2025-06-02

本研究通过荟萃分析6项随机对照试验共1544例非急性硬膜下血肿患者,评估辅助脑膜中动脉栓塞(MMAE)的疗效与安全性。结果显示辅助MMAE显著降低血肿复发率(8% vs 15.6%;RR 0.52)和手术挽救率(4.5% vs 12.7%;RR 0.36),但感染率较高(8.4% vs 4.8%;RR 1.81),其他不良事件无显著差异。

要点

  • 辅助MMAE可显著降低非急性硬膜下血肿复发和手术挽救风险。
  • MMAE组感染率较高,但严重不良事件、颅内出血、卒中及死亡率无显著差异。
  • 证据确定性经GRADE评估,试验序贯分析支持结果可靠性。

核心结论

  • 辅助MMAE可降低非急性硬膜下血肿的复发率和手术挽救率,安全性可接受但感染率增加。

研究设计与样本

  • 采用GRADE系统评估证据确定性,并进行试验序贯分析。

主要发现

  • 辅助MMAE组血肿复发率为8%,标准治疗组为15.6%(RR 0.52;95%CI 0.37-0.73;P<0.01)。
  • 辅助MMAE组手术挽救率为4.5%,标准治疗组为12.7%(RR 0.36;95%CI 0.25-0.53;P<0.01)。
  • 非手术复发、血肿体积、厚度及住院时间无显著差异(P值分别为0.94、0.18、0.34、0.37)。
  • MMAE组感染率为8.4%,标准治疗组为4.8%(RR 1.81;95%CI 1.23-2.66;P<0.01)。
  • 不良事件、严重不良事件、颅内出血、卒中及死亡率无显著差异。

关键数值与推荐

  • 血肿复发:8% vs 15.6%,RR 0.52(95%CI 0.37-0.73),P<0.01。
  • 手术挽救:4.5% vs 12.7%,RR 0.36(95%CI 0.25-0.53),P<0.01。
  • 感染:8.4% vs 4.8%,RR 1.81(95%CI 1.23-2.66),P<0.01。

临床怎么用

  • 对于非急性硬膜下血肿,在标准治疗基础上可考虑辅助MMAE以降低复发和手术挽救风险。
  • 需警惕MMAE相关感染风险增加,权衡获益与感染风险。

局限性

  • 平均随访仅4.7个月,需要更大规模、更长随访的试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Non-acute subdural hematoma (NASDH) is a prevalent neurological condition, encompassing chronic and subacute types. Despite standard-care, including surgical evacuation and medical management, recurrence rates remain high. Emerging evidence suggests that middle meningeal artery embolization (MMAE) as an adjunctive procedure may reduce recurrence. This study evaluates the efficacy and safety of MMAE in NASDH. METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) retrieved from PubMed, EMBASE, WOS, Scopus, and Cochrane until November 2024. The analysis presented risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, with 95% confidence intervals (CI) using R software. The GRADE system assessed evidence certainty, alongside trial sequential analysis for result reliability. PROSPERO ID: CRD42024625504. RESULTS: Six RCTs and 1,544 patients were included, with an average of 4.7 months follow-up. Adjunctive MMAE, compared to standard-care, significantly reduced hematoma recurrence (8% vs 15.6%; RR: 0.52; 95% CI: [0.37:0.73]; P < 0.01) and surgical rescue (4.5% vs. 12.7%; RR: 0.36; 95% CI: [0.25:0.53]; P < 0.01). However, no significant effect was found for recurrence without surgery (P = 0.94), hematoma volume (P = 0.18), thickness (P = 0.34), or hospital stay (P = 0.37). Infection rates were higher with MMAE (8.4% vs. 4.8%; RR: 1.81; 95% CI: [1.23:2.66]; P < 0.01), but adverse events (AEs), serious AEs, intracranial hemorrhage, stroke, and mortality showed no significant differences. CONCLUSION: Adjunctive MMAE reduced hematoma recurrence and surgical rescue rates in NASDH with an acceptable safety profile despite increased infection rates. However, further large-scale trials with extended follow-ups are needed.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Elgendy MS, Rifai M, Taha AM, et al. Adjunctive middle meningeal artery embolization for non-acute subdural hematoma: A GRADE-assessed meta-analysis and trial sequential analysis on randomized trials. Acta Neurochir (Wien). 2025. PMID: 40455367. doi:10.1007/s00701-025-06574-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。